Investor Presentaiton

Strong momentum in Interventional Urology with broad-based growth of 17%, led by the US Men's Health business Interventional Urology performance 23 19 18 19 13 17 11 12 9 11 686 643 642 667 . 560 Q2 2022/23 highlights Growth in the quarter was driven by continued strong momentum across business areas and geographies, as well as positive impact from a lower baseline in the US last year Men's Health was the largest contributor to growth in Q2 driven mainly by the TitanⓇ penile implants in the US Endourology in Europe and Women's Health in the US also made a solid contribution to growth Coloplast has launched its first laser equipment, Thulium Fiber Laser (TFL) Drive, in key markets. The launch is off to a good start with positive customer feedback The launch is part of Coloplast's strategy to expand into adjacent segments, and enables Coloplast to compete in the lasers market, worth an estimated DKK 3 billion 10 Q2 21/22 Q3 21/22 Revenues (DKKm) Q4 21/22 Organic growth (%) Q1 22/23 Q2 22/23 Reported growth (%) Coloplast

View entire presentation